Wellington Management Group LLP Buys 727,665 Shares of Dr. Reddy's Laboratories Limited (NYSE:RDY)

Wellington Management Group LLP lifted its stake in shares of Dr. Reddy's Laboratories Limited (NYSE:RDY - Free Report) by 431.8% during the fourth quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The institutional investor owned 896,165 shares of the company's stock after purchasing an additional 727,665 shares during the period. Wellington Management Group LLP owned 0.11% of Dr. Reddy's Laboratories worth $14,150,000 at the end of the most recent quarter.

Other large investors also recently made changes to their positions in the company. Royal Bank of Canada increased its holdings in shares of Dr. Reddy's Laboratories by 403.1% in the fourth quarter. Royal Bank of Canada now owns 10,037,246 shares of the company's stock valued at $158,489,000 after purchasing an additional 8,042,163 shares during the last quarter. Renaissance Technologies LLC grew its stake in Dr. Reddy's Laboratories by 382.9% during the fourth quarter. Renaissance Technologies LLC now owns 9,418,428 shares of the company's stock worth $148,717,000 after buying an additional 7,467,979 shares in the last quarter. Aikya Investment Management Ltd increased its stake in shares of Dr. Reddy's Laboratories by 416.1% in the 4th quarter. Aikya Investment Management Ltd now owns 5,610,503 shares of the company's stock valued at $88,590,000 after purchasing an additional 4,523,303 shares during the last quarter. Dimensional Fund Advisors LP raised its holdings in shares of Dr. Reddy's Laboratories by 405.9% during the 4th quarter. Dimensional Fund Advisors LP now owns 5,361,013 shares of the company's stock worth $84,643,000 after buying an additional 4,301,212 shares in the last quarter. Finally, Vanguard Group Inc. lifted its position in shares of Dr. Reddy's Laboratories by 397.2% during the 4th quarter. Vanguard Group Inc. now owns 4,896,185 shares of the company's stock worth $77,311,000 after buying an additional 3,911,404 shares during the last quarter. Institutional investors and hedge funds own 3.85% of the company's stock.

Wall Street Analyst Weigh In

Separately, Wall Street Zen upgraded Dr. Reddy's Laboratories from a "hold" rating to a "buy" rating in a report on Thursday, May 8th.

Dr. Reddy's Laboratories Stock Performance

Dr. Reddy's Laboratories stock traded down $0.08 during trading on Tuesday, hitting $14.66. The stock had a trading volume of 1,240,450 shares, compared to its average volume of 1,481,999. The stock has a market cap of $12.24 billion, a price-to-earnings ratio of 23.34 and a beta of 0.33. The company has a quick ratio of 1.38, a current ratio of 1.92 and a debt-to-equity ratio of 0.02. The stock's 50 day moving average is $13.71 and its two-hundred day moving average is $14.01. Dr. Reddy's Laboratories Limited has a 1 year low of $12.26 and a 1 year high of $16.89.

Dr. Reddy's Laboratories (NYSE:RDY - Get Free Report) last issued its quarterly earnings results on Friday, May 9th. The company reported $0.22 EPS for the quarter, topping analysts' consensus estimates of $0.20 by $0.02. Dr. Reddy's Laboratories had a net margin of 17.25% and a return on equity of 17.87%. The firm had revenue of $996.17 million for the quarter, compared to analyst estimates of $83.70 billion. As a group, analysts predict that Dr. Reddy's Laboratories Limited will post 0.8 EPS for the current year.

Dr. Reddy's Laboratories Company Profile

Dr. Reddy's Laboratories Limited, together with its subsidiaries, operates as an integrated pharmaceutical company worldwide. It operates through Global Generics, Pharmaceutical Services and Active Ingredients (PSAI), and Others segments. The company's Global Generics segment manufactures and markets prescription and over-the-counter finished pharmaceutical products that are marketed under a brand name or as a generic finished dosages with therapeutic equivalence to branded formulations, as well as engages in the biologics business.